Proteo, Inc. and its wholly-owned subsidiary Proteo Biotech AG announced today the signing of a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). Under the agreement Proteo will provide USAMRIID with Elafin and related scientific data in order to plan and conduct preclinical research on the development of new therapeutic strategies to combat life-threatening infectious diseases.
Scientists from the U.S. Army Medical Research Institute of Infectious Diseases are investigating therapies to treat individuals that have become symptomatic after exposure to one of the bacterial bio-threat agents (anthrax, plague, tularemia, glanders or melioidosis). One direction their research has taken is to attempt to mitigate or alter the immunological response that in many cases is the ultimate cause of death in these infections. They are interested in investigating if Proteo’s Elafin could help as a co-therapy with antibiotics.
Proteo’s CEO, Birge Bargmann: “We are looking forward to the results of the U.S. Army Medical Research Institute of Infectious Diseases regarding the use of our Lead Product, Elafin, in preclinical models”.
